Biotechnology The UK regulator has granted conditional marketing authorization for Nexpovio (selinexor) in combination with dexamethasone to treat multiple myeloma in adults who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. 2 June 2021